The double-blind variable placebo lead-in period: Results from two antidepressant clinical trials

Journal of Clinical Psychopharmacology

Volumn 21, Issue 6, 2001, Pages 561-568

  Faries, Douglas E ^a   Heiligenstein, John H ^a   Tollefson, Gary D ^a   Potter, William Z ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; FLUOXETINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; HUMAN; METHODOLOGY; PERFORMANCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZATION; SAMPLING; SINGLE BLIND PROCEDURE;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; SINGLE-BLIND METHOD;

EID: 0035195571     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200112000-00004     Document Type: Article

References (11)

1. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?
2. Run-in periods in randomized trials
3. Baseline characteristics of 10-day placebo washout responders in antidepressant trials
4. The introductory placebo washout: A retrospective evaluation
5. Placebo run-in period in studies of depressive disorders
6. The problem of measurement error in multisite clinical trials
7. The failure of placebo-controlled studies
8. New approaches to the design of antidepressant trials: Empirical validation
9. The impact of restrictive entry criterion during the placebo lead-in period
10. LY248686, A new inhibitor of serotonin and norepinephrine uptake
11. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor